DK0512042T3 - GLP-1-analoger anvendelige ved diabetesbehandling - Google Patents

GLP-1-analoger anvendelige ved diabetesbehandling

Info

Publication number: DK0512042T3
Authority: DK; Denmark
Prior art keywords: analogs; glp; amino acid; acid substitutions; positions
Prior art date: 1990-01-24

Application number

DK91903738.2T

Other languages

English (en)

Inventor

Douglas I Buckley

Joel F Habener

Joanne B Mallory

Sveltana Mojsov

Original Assignee

Douglas I Buckley

Joel F Habener

Joanne B Mallory

Mojsov Svetlana

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-24

Filing date

1991-01-24

Publication date

1998-05-11

1991-01-24 Application filed by Douglas I Buckley, Joel F Habener, Joanne B Mallory, Mojsov Svetlana filed Critical Douglas I Buckley

1998-05-11 Application granted granted Critical

1998-05-11 Publication of DK0512042T3 publication Critical patent/DK0512042T3/da

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
150000001413 amino acids Chemical group 0.000 abstract 3
238000006467 substitution reaction Methods 0.000 abstract 3
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
150000008574 D-amino acids Chemical group 0.000 abstract 1
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DK91903738.2T 1990-01-24 1991-01-24 GLP-1-analoger anvendelige ved diabetesbehandling DK0512042T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46873690A	1990-01-24	1990-01-24

Publications (1)

Publication Number	Publication Date
DK0512042T3 true DK0512042T3 (da)	1998-05-11

Family

ID=23861028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK91903738.2T DK0512042T3 (da)	1990-01-24	1991-01-24	GLP-1-analoger anvendelige ved diabetesbehandling

Country Status (8)

Country	Link
EP (1)	EP0512042B1 (da)
JP (5)	JP3262329B2 (da)
AT (1)	ATE164852T1 (da)
CA (1)	CA2073856C (da)
DE (1)	DE69129226T2 (da)
DK (1)	DK0512042T3 (da)
ES (1)	ES2113879T3 (da)
WO (1)	WO1991011457A1 (da)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en)	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en)	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DK36492D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
USRE37302E1 (en) *	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
RU2128663C1 (ru) *	1992-06-15	1999-04-10	Скиос Инк.	Производные полипептида, обладающие инсулинотропной активностью, фармацевтическая композиция, способы усиления действия инсулина, способы лечения диабета
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) *	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) *	1993-12-09	1995-06-21	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (da) *	1993-12-23	1993-12-23	Novo Nordisk As
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US5574008A (en) *	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
AU5685296A (en) *	1995-05-17	1996-11-29	Novo Nordisk A/S	Immunoassay for glucagon like protein 1 (glp-1) in plasma
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP0929576A1 (en) *	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivatives
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
BRPI9711437B8 (pt) *	1996-08-30	2021-05-25	Novo Nordisk As	derivados de glp-1
EP1566180A3 (en) *	1996-08-30	2007-08-08	Eli Lilly & Company	Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0996459B1 (en)	1997-01-07	2005-09-21	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the reduction of food intake
US5981488A (en) *	1997-03-31	1999-11-09	Eli Lillly And Company	Glucagon-like peptide-1 analogs
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
DE59811840D1 (de) *	1997-09-12	2004-09-23	Pharis Biotec Gmbh	Zusammensetzung zur therapie von diabetes mellitus und fettsucht
CA2310097C (en)	1997-11-14	2014-07-29	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
WO1999029336A1 (en) *	1997-12-05	1999-06-17	Eli Lilly And Company	Glp-1 formulations
EP1052994A2 (en)	1998-02-02	2000-11-22	Trustees Of Tufts College	Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
EP1062240B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
EP1056775B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1061946B1 (en) *	1998-02-27	2004-04-28	Novo Nordisk A/S	Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
FR2777283B1 (fr) *	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH11328947A (ja)	1998-05-18	1999-11-30	Nec Corp	大規模ｆｉｆｏ回路
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000007617A1 (en)	1998-07-31	2000-02-17	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
EP1666054A1 (en)	1998-08-28	2006-06-07	Eli Lilly & Company	Method for administering insulinotropic peptides
CN1317967A (zh)	1998-09-17	2001-10-17	伊莱利利公司	蛋白质制剂
US6461834B1 (en)	1998-11-06	2002-10-08	Bionebraska, Inc.	Clostripain catalyzed amidation of peptides
US6903186B1 (en) *	1998-12-07	2005-06-07	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S	Analogues of GLP-1
DK1137666T5 (da) *	1998-12-07	2009-10-05	Univ Tulane	GLP-1-analoger
DK1137667T3 (da) *	1998-12-07	2005-02-14	Sod Conseils Rech Applic	GLP-1-analoger
US7425541B2 (en) *	1998-12-11	2008-09-16	Medarex, Inc.	Enzyme-cleavable prodrug compounds
EP1600162A1 (en)	1998-12-22	2005-11-30	Eli Lilly & Company	Shelf-stable formulation of glucagon-like peptide-1
US6927214B1 (en)	1999-01-15	2005-08-09	Novo Nordisk A/S	Non-peptide GLP-1 agonists
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
EP1163268B1 (en)	1999-03-15	2011-05-11	Novo Nordisk A/S	Ion exchange chromatographic separation of glp-1 and related peptides
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
PT1180121E (pt)	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
US6309633B1 (en) *	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
DE19940130A1 (de)	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US7229793B1 (en) *	1999-11-19	2007-06-12	Shire Human Genetic Therapies, Inc.	Constructs and cells for production of small peptides
PT1741445E (pt)	2000-01-21	2013-11-11	Novartis Ag	Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
EP1263458B1 (en)	2000-03-08	2005-11-16	Novo Nordisk A/S	Lowering serum cholesterol
ES2529300T3 (es)	2000-04-12	2015-02-18	Novozymes Biopharma Dk A/S	Proteínas de fusión de albúmina
ES2321439T3 (es) *	2000-06-16	2009-06-05	ELI LILLY & COMPANY	Analogos del peptido-1 similar a glucagon.
PE20020617A1 (es)	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
EP1970072A1 (en)	2000-09-18	2008-09-17	Sanos Bioscience A/S	Use of GLP-2 peptides for the treatment of hyperparathyroidism
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
EP2062593A3 (en)	2000-12-01	2011-08-17	Takeda Pharmaceutical Company Limited	Method for producing preparation containing bioactive peptide
AU2002228608A1 (en)	2000-12-13	2002-06-24	Eli Lilly And Company	Amidated glucagon-like peptide-1
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
US6890905B2 (en)	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
CN1162446C (zh)	2001-05-10	2004-08-18	上海华谊生物技术有限公司	促胰岛素分泌肽衍生物
DE10150203A1 (de)	2001-10-12	2003-04-17	Probiodrug Ag	Peptidylketone als Inhibitoren der DPIV
US7368421B2 (en)	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en)	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7101843B2 (en)	2001-08-23	2006-09-05	Eli Lilly And Company	Glucagon-like peptide-1 analogs
US6844316B2 (en)	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
US7041646B2 (en)	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US6864069B2 (en)	2001-10-05	2005-03-08	Bayer Pharmaceuticals Corporation	Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AR036711A1 (es) *	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
ES2425738T3 (es)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
KR101165431B1 (ko)	2002-02-20	2012-07-12	에미스페어 테크놀로지스, 인코포레이티드	Ｇｌｐ-1 분자의 투여 방법
CN1622941A (zh)	2002-02-28	2005-06-01	普罗西迪恩有限公司	基于谷氨酰胺酰基的dpiv抑制剂
EP1525219B1 (en)	2002-07-04	2009-05-27	Zealand Pharma A/S	Glp-1 and methods for treating diabetes
CA2497794A1 (en) *	2002-09-06	2004-03-18	Bayer Pharmaceuticals Corporation	Modified glp-1 receptor agonists and their pharmacological methods of use
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
WO2004029081A2 (en)	2002-09-25	2004-04-08	Theratechnologies Inc.	Modified glp-1 peptides with increased biological potency
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2004087910A1 (ja) *	2003-03-28	2004-10-14	National Institute Of Agrobiological Sciences	組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
NZ568459A (en)	2003-05-05	2009-06-26	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
ZA200508439B (en)	2003-05-05	2007-03-28	Probiodrug Ag	Medical use of inhibitors of glutaminyl and glutamate cyclases
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7008957B2 (en)	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en)	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en)	2003-07-28	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de)	2003-08-01	2005-02-03	Aventis Pharma Deutschland Gmbh	Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
ZA200602051B (en)	2003-08-13	2007-10-31	Takeda Pharmaceutical	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005019261A1 (en)	2003-08-21	2005-03-03	Novo Nordisk A/S	Separation of polypeptides comprising a racemized amino acid
TW200526254A (en)	2003-09-19	2005-08-16	Novo Nordisk As	Novel GLP-1 derivatives
NZ546322A (en)	2003-10-15	2008-11-28	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
HUE043210T2 (hu)	2003-11-20	2019-08-28	Novo Nordisk As	Injekciós eszközök elõállítására optimális propilénglikol-tartalmú peptidkészítmények
DE602004031455D1 (de)	2003-12-09	2011-03-31	Novo Nordisk As	Regulierung der nahrungspräferenz mit glp-1-agonisten
WO2005058955A1 (en)	2003-12-16	2005-06-30	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues of glp-1
WO2005058252A2 (en) *	2003-12-16	2005-06-30	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Glp-1 pharmaceutical compositions
BRPI0417717A (pt)	2003-12-18	2007-04-03	Novo Nordisk As	composto, composição farmacêutica, e, uso de um composto
JP2007537149A (ja) *	2004-01-08	2007-12-20	セラテクノロジーズインコーポレイテッド	長時間作用性のグルカゴン様ペプチド−１類似体
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
KR20120034237A (ko)	2004-02-11	2012-04-10	아밀린 파마슈티칼스, 인크.	선택가능한 특성을 갖는 하이브리드 폴리펩티드
US8410047B2 (en)	2004-06-11	2013-04-02	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
EP1771573A4 (en) *	2004-07-21	2009-02-18	Ambrx Inc	BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
BRPI0518761A2 (pt)	2004-12-02	2008-12-09	Domantis Ltd	fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
US8404637B2 (en)	2005-02-11	2013-03-26	Amylin Pharmaceuticals, Llc	GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
RU2007134155A (ru)	2005-03-18	2009-04-27	Ново Нордиск А/С (DK)	Glp-1 соединения с увеличенным временем полужизни
EP1888103B1 (en)	2005-04-11	2012-03-21	Amylin Pharmaceuticals, Inc.	Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
EP1889618A4 (en) *	2005-05-27	2010-11-24	Daiichi Sankyo Co Ltd	Combined drug for treating diabetes
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
HRP20140091T4 (hr)	2005-09-14	2021-12-24	Takeda Pharmaceutical Company Limited	Davanje inhibitora dipeptidil peptidaze
ZA200802857B (en)	2005-09-14	2009-09-30	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
PT1767545E (pt)	2005-09-22	2010-02-05	Biocompatibles Uk Ltd	Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
EP1943275B1 (en) *	2005-11-01	2010-06-16	Activotec SPP Limited	Insulinotropic compounds and uses thereof
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
CN100374462C (zh) *	2005-11-21	2008-03-12	大连帝恩生物工程有限公司	截短胰高血糖素样肽1(sGLP-1)、制法及其应用
JPWO2007063907A1 (ja) *	2005-11-30	2009-05-07	塩野義製薬株式会社	ペプチド糖鎖付加体およびそれを有効成分とする医薬
WO2007075534A2 (en)	2005-12-16	2007-07-05	Nektar Therapeutics Al, Corporation	Polymer conjugates of glp-1
EP2007804B1 (en)	2006-04-20	2014-06-18	Amgen, Inc	Glp-1 compounds
JP2009535380A (ja) *	2006-05-02	2009-10-01	アクトジェニックス・エヌブイ	肥満関連ペプチドの微生物性腸送達
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2008216265B2 (en)	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
RU2350324C1 (ru) *	2007-08-02	2009-03-27	Закрытое акционерное общество "Биологические исследования и системы"	Способ лечения сахарного диабета 2 типа, осложненного полиневропатией
WO2009030774A1 (en) *	2007-09-05	2009-03-12	Novo Nordisk A/S	Truncated glp-1 derivatives and their therapeutical use
WO2009030738A1 (en)	2007-09-05	2009-03-12	Novo Nordisk A/S	Glucagon-like peptide-1 derivatives and their pharmaceutical use
AU2008318876B2 (en)	2007-10-30	2014-05-15	Indiana University Research And Technology Corporation	Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US20110065633A1 (en)	2008-01-30	2011-03-17	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
CA2718480A1 (en)	2008-03-31	2009-10-08	Glaxo Group Limited	Drug fusions and conjugates
PA8830501A1 (es)	2008-06-17	2010-07-27	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
CL2009001425A1 (es)	2008-06-17	2010-04-30	Univ Indiana Res & Tech Corp	Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
KR20110039348A (ko)	2008-08-06	2011-04-15	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8889618B2 (en)	2008-11-07	2014-11-18	The General Hospital Corporation	C-terminal fragments of glucagon-like peptide-1 (GLP-1)
WO2010066734A1 (en)	2008-12-08	2010-06-17	Novo Nordisk A/S	Counter current purification of polypeptides
ES2620610T3 (es) *	2008-12-10	2017-06-29	Glaxosmithkline Llc	Composiciones farmacéuticas de albiglutide
EP2376097A4 (en) *	2008-12-19	2012-10-03	Univ Indiana Res & Tech Corp	PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
WO2010084173A1 (en)	2009-01-22	2010-07-29	Novo Nordisk Health Care Ag	Stable growth hormone compounds
EA021146B1 (ru)	2009-03-27	2015-04-30	Глаксо Груп Лимитед	Продукты слияния и конъюгаты лекарственных средств
JP5659224B2 (ja)	2009-05-15	2015-01-28	ノバルティスアーゲー	アルドステロンシンターゼ阻害剤としてのアリールピリジン
KR20120036850A (ko)	2009-05-15	2012-04-18	노파르티스 아게	알도스테론 신타제 억제제로서의 벤족사졸론 유도체
UY32660A (es)	2009-05-28	2010-12-31	Novartis Ag	Derivados aminobutricos sustituidos como inhibidores de neprilisina
ME01923B (me)	2009-05-28	2015-05-20	Novartis Ag	Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
MX2011013625A (es)	2009-06-16	2012-01-20	Univ Indiana Res & Tech Corp	Compuestos glucagon activo de receptor de gip.
CN102612376A (zh)	2009-08-06	2012-07-25	诺沃-诺迪斯克保健股份有限公司	具有延长的体内功效的生长激素
EA201290123A1 (ru)	2009-09-30	2012-10-30	Глаксо Груп Лимитед	Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
WO2011041293A1 (en)	2009-09-30	2011-04-07	Takeda Pharmaceutical Company Limited	Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
ES2663351T3 (es)	2009-11-17	2018-04-12	Novartis Ag	Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102666535B (zh)	2009-11-30	2015-02-25	诺华股份有限公司	作为醛固酮合酶抑制剂的咪唑衍生物
AU2010338387B2 (en) *	2009-12-16	2014-10-23	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
CA2787895A1 (en)	2010-01-22	2011-07-28	Novo Nordisk Health Care Ag	Stable growth hormone compounds
MX345736B (es)	2010-01-22	2017-02-14	Novo Nordisk Healthcare Ag	Hormonas de crecimiento con eficacia in vivo prolongada.
US8551946B2 (en)	2010-01-27	2013-10-08	Indiana University Research And Technology Corporation	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
CN102834393B (zh)	2010-02-03	2015-07-22	武田药品工业株式会社	细胞凋亡信号调节激酶1抑制剂
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
KR20130098873A (ko)	2010-04-27	2013-09-05	질랜드 파마 에이/에스	Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
WO2011136361A1 (ja)	2010-04-30	2011-11-03	株式会社三和化学研究所	生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
AU2010353685B2 (en)	2010-05-17	2014-09-25	Betta Pharmaceuticals Co., Ltd.	Novel glucagon like peptide analogs, composition, and method of use
CN103119057B (zh)	2010-06-24	2016-06-15	印第安纳大学研究及科技有限公司	基于酰胺的胰岛素前药
US8778872B2 (en)	2010-06-24	2014-07-15	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
WO2012054822A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Glp-1 polymer conjugates having a releasable linkage
US9040481B2 (en)	2010-11-02	2015-05-26	The General Hospital Corporation	Methods for treating steatotic disease
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
EP2654773B1 (en)	2010-12-22	2018-10-03	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
WO2012121302A1 (ja)	2011-03-08	2012-09-13	株式会社三和化学研究所	分析方法
WO2012136792A2 (en)	2011-04-07	2012-10-11	Glaxo Group Limited	Cck compositions
WO2012136790A1 (en)	2011-04-07	2012-10-11	Glaxo Group Limited	Compositions comprising fusion proteins or conjugates with an improved half -life
CN106117343B (zh)	2011-04-12	2020-11-03	诺沃—诺迪斯克有限公司	双酰化glp-1衍生物
JP6179864B2 (ja)	2011-06-22	2017-08-16	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
CA2839867A1 (en)	2011-06-22	2012-12-27	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
WO2013004983A1 (en)	2011-07-04	2013-01-10	Imperial Innovations Limited	Novel compounds and their effects on feeding behaviour
WO2013006692A2 (en)	2011-07-06	2013-01-10	The General Hospital Corporation	Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
EP2771025A1 (en) *	2011-10-28	2014-09-03	Pharis Biotec GmbH	A polypeptide for the protection against heart ischemia-reperfusion injury
MX2014005351A (es)	2011-11-03	2014-05-28	Zealand Pharma As	Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
US20150038417A1 (en) *	2011-12-09	2015-02-05	Novo Nordisk A/S	GLP-1 Agonists
CA2868188A1 (en)	2012-03-22	2013-09-26	Novo Nordisk A/S	Compositions of glp-1 peptides and preparation thereof
DK2827845T3 (da)	2012-03-22	2019-04-01	Novo Nordisk As	Sammensætninger omfattende et fremføringsmiddel og fremstilling deraf
WO2013171570A1 (en)	2012-05-16	2013-11-21	Glaxo Group Limited	Polypeptide loaded poca nanoparticles for oral administration
CN104487056A (zh)	2012-06-20	2015-04-01	诺和诺德A/S（股份有限公司）	包含肽和递送剂的片剂制剂
EP2864351B1 (en)	2012-06-21	2016-08-10	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
JP6224586B2 (ja)	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
NZ704043A (en)	2012-07-23	2017-07-28	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
LT2956464T (lt)	2013-02-14	2018-07-10	Novartis Ag	Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
US9789164B2 (en)	2013-03-15	2017-10-17	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
ES2841123T3 (es)	2013-04-05	2021-07-07	Formulacion Del Compuesto De La Hormona De Crecimiento	Formulación del compuesto de la hormona de crecimiento
PE20151808A1 (es)	2013-05-02	2015-12-16	Glaxosmithkline Ip Dev Ltd	Peptidos terapeuticos
AU2014261336B2 (en)	2013-05-02	2019-02-28	Novo Nordisk A/S	Oral dosing of GLP-1 compounds
AP2016009019A0 (en)	2013-07-25	2016-02-29	Novartis Ag	Bioconjugates of synthetic apelin polypeptides
JP6501775B2 (ja)	2013-07-25	2019-04-17	ノバルティスアーゲー	心不全治療用の環状ポリペプチド
HRP20181505T1 (hr)	2013-10-17	2018-11-02	Zealand Pharma A/S	Acilirani analozi glukagona
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
MX369770B (es)	2013-11-06	2019-11-21	Zealand Pharma As	Compuestos agonistas triples de glucagón-glp-1-gip.
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
PE20171328A1 (es)	2015-01-23	2017-09-12	Novartis Ag	Conjugados de acidos grasos y apelina sintetica con mayor vida media
KR20170137198A (ko)	2015-04-16	2017-12-12	질랜드 파마 에이/에스	아실화된 글루카곤 유사체
WO2017210100A1 (en) *	2016-06-02	2017-12-07	Indiana University Research And Technology Corporation	Glucagon-like peptide-1-t3 conjugates
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
JP6563614B1 (ja)	2016-12-09	2019-08-21	ジーランド・ファーマ・ア／エス	アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
CN109836504B (zh) *	2017-11-24	2022-08-02	浙江道尔生物科技有限公司	一种治疗代谢疾病的多结构域活性蛋白
KR102647171B1 (ko)	2018-02-02	2024-03-15	노보 노르디스크 에이/에스	Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3887388A1 (en)	2018-11-27	2021-10-06	Novartis AG	Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
UY38485A (es)	2018-11-27	2020-06-30	Novartis Ag	Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en)	2018-11-27	2023-03-23	Novartis Ag	Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
GB201917723D0 (en)	2019-12-04	2020-01-15	Nv Rose Llc	Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
CA3193453A1 (en)	2020-09-30	2022-04-07	Beijing Ql Biopharmaceutical Co., Ltd.	Polypeptide conjugates and methods of uses
TW202333563A (zh)	2021-11-12	2023-09-01	瑞士商諾華公司	用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
JP2025512832A (ja)	2022-03-30	2025-04-22	ベイジンキューエルバイオファーマシューティカルカンパニー，リミテッド	ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CN114958883B (zh) *	2022-04-12	2023-01-31	北京惠之衡生物科技有限公司	一种表达glp-1类似物的重组工程菌及其构建方法
JPWO2024106505A1 (da) *	2022-11-16	2024-05-23
WO2024241229A1 (en)	2023-05-24	2024-11-28	Novartis Ag	Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE110083T1 (de) *	1986-05-05	1994-09-15	Gen Hospital Corp	Insulinotropes hormon.

1991
- 1991-01-24 JP JP50361891A patent/JP3262329B2/ja not_active Expired - Lifetime
- 1991-01-24 AT AT91903738T patent/ATE164852T1/de not_active IP Right Cessation
- 1991-01-24 CA CA002073856A patent/CA2073856C/en not_active Expired - Lifetime
- 1991-01-24 EP EP91903738A patent/EP0512042B1/en not_active Expired - Lifetime
- 1991-01-24 ES ES91903738T patent/ES2113879T3/es not_active Expired - Lifetime
- 1991-01-24 DE DE69129226T patent/DE69129226T2/de not_active Expired - Lifetime
- 1991-01-24 WO PCT/US1991/000500 patent/WO1991011457A1/en not_active Ceased
- 1991-01-24 DK DK91903738.2T patent/DK0512042T3/da active
2000
- 2000-10-11 JP JP2000311202A patent/JP2001151798A/ja active Pending
2002
- 2002-10-30 JP JP2002315982A patent/JP2003192698A/ja active Pending
2004
- 2004-03-19 JP JP2004081117A patent/JP2004196825A/ja active Pending
2005
- 2005-01-28 JP JP2005022265A patent/JP2005132848A/ja active Pending

Also Published As

Publication number	Publication date
CA2073856A1 (en)	1991-07-25
EP0512042B1 (en)	1998-04-08
JP2004196825A (ja)	2004-07-15
JP2001151798A (ja)	2001-06-05
DE69129226D1 (de)	1998-05-14
EP0512042A1 (en)	1992-11-11
ATE164852T1 (de)	1998-04-15
EP0512042A4 (en)	1993-02-17
CA2073856C (en)	2002-12-03
WO1991011457A1 (en)	1991-08-08
DE69129226T2 (de)	1998-07-30
JP2003192698A (ja)	2003-07-09
JP3262329B2 (ja)	2002-03-04
ES2113879T3 (es)	1998-05-16
JP2005132848A (ja)	2005-05-26
JPH05506427A (ja)	1993-09-22

Publication	Publication Date	Title
DK0512042T3 (da)	1998-05-11	GLP-1-analoger anvendelige ved diabetesbehandling
DE69531889D1 (de)	2003-11-13	Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
US20240376175A1 (en)	2024-11-14	Novel GLP-1 Analogues
RU2208015C2 (ru)	2003-07-10	Аналоги гпп-1
ES2247676T3 (es)	2006-03-01	Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
ES2359031T3 (es)	2011-05-17	Composición farmacéutica que comprende un péptido de exendina-4.
JP2005530732A5 (da)	2006-05-18
MY121291A (en)	2006-01-28	Fracture healing using pthrp analogs
MXPA01009805A (es)	2004-07-30	Peptido.
ATE458054T1 (de)	2010-03-15	Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
ATE402957T1 (de)	2008-08-15	Analoge des menschlichen interferon-alpha mit niedriger toxizität
EP0333356A3 (en)	1990-12-19	Hirudin peptides
ATE193541T1 (de)	2000-06-15	Insulinotropes hormon
KR950701818A (ko)	1995-05-17	탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
CA2069943A1 (en)	1991-06-06	Synthetic calcitonin peptides
DK0523330T3 (da)	1996-04-15	Implanterbare sammensætninger indeholdende et biologisk aktivt protein, peptid eller polypeptid
AU2003303218A8 (en)	2004-07-14	Peptides and their use for the treatment of hiv infections
DK119391A (da)	1991-08-22	Humaninsulinanaloger
ECSP951557A (es)	1997-07-28	Analogos composiciones y procedimientos de uso de peptidos insulinotropicos similares al glucagon
DE69707690D1 (de)	2001-11-29	Neue peptide und nootroper wirkstoff
TH50339B (th)	2016-07-07	การสมานรอยหักของกระดูกโดยใช้อานาลอกของ PTHrP
TH26711A (th)	1997-10-16	" สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos
TH40579A (th)	2000-10-03	การสมานรอยหักของกระดูกโดยใช้อานาลอกของ PTHrP
TH44085A (th)	2001-04-02	อะนาลอกของ flint ที่ทนต่อโปรตีเอส